AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27153246
Drug: faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: faldaprevir 240 mg q.d. for 24 weeks plus PegIFNα-2b/RBV for 48 weeks
Trial: 27153246
Drug: faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: faldaprevir 120 mg q.d. plus PegIFNα-2b/RBV
Trial: 27153752
Drug: EHR patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHR patient portal message promoting influenza vaccines and offering online appointment scheduling
Trial: 27154719
Drug: Activated protein
RxNorm normalized name: Activated protein C
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated protein C (DAA) 24 mg/kg/h for 96 h
Trial: 27154719
Drug: Hydrocortisone 50
RxNorm normalized name: hydrocortisone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 50 mg intravenous bolus q6 for 7 days
Trial: 27154719
Drug: Fludrocortisone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone 50 µg once daily for 7 days
Trial: 27154719
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DAA and corticosteroids
Trial: 27156227
Drug: Onalespib (AT13387)
RxNorm normalized name: Onalespib
DrugBank: Onalespib (DB06306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onalespib (AT13387) 150-220 mg/m² once-weekly intravenous for 3 weeks and imatinib 400 mg daily
Trial: 27157491
Drug: Pembrolizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (10 mg/kg intravenously every 2 weeks for 24 months)
Trial: 27158544
Drug: PEG 3350
RxNorm normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 3350 17 g once daily for 7 days
Trial: 27165786
Drug: Mecillinam (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecillinam (400 mg pivmecillinam hydrochloride three times a day for 7 days)
Trial: 27167058
Drug: Intraoperative fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative fluid challenge with 10 ml/kg of 0.9% normal saline
Trial: 27167209
Drug: Oral macrolides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral macrolides after an initial 4-week IV amikacin and cefoxitin (or imipenem) treatment
Trial: 27167209
Drug: Oral macrolides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral macrolides after an initial 2-week IV amikacin and cefoxitin (or imipenem) treatment
Trial: 27169385
Drug: Evofosfamide (Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evofosfamide (Arm A) - 30-60 min/day infusion on Days 1-5 of a 21-day cycle
Trial: 27169385
Drug: Evofosfamide (Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evofosfamide (Arm B) - Continuous infusion over 120 hr on Days 1-5 of a 21-day cycle
Trial: 27169478
Drug: Isavuconazole (ISAV)
RxNorm normalized name: isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole (ISAV) 200 mg 3 times daily for 2 days followed by 200 mg once-daily (IV or PO)
Trial: 27169571
Drug: Complementary/integrative medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary/integrative medicine (CIM) treatment
Trial: 27169792
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg everolimus once daily
Trial: 27169903
Drug: Cenicriviroc 150
RxNorm normalized name: Cénicriviroc
DrugBank: Cenicriviroc (DB11758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenicriviroc 150 mg once daily for 14 days
Trial: 27171984
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with vincristine, prednisone, doxorubicin, and pegylated asparaginase; Imatinib for Philadelphia chromosome-positive disease; followed by consolidation with clofarabine.
Trial: 27172991
Drug: Sloped shoulder
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sloped shoulder configuration implants
Trial: 27174159
Drug: Other oral
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other oral continuous combined HRT (HRTcc)
Trial: 27175116
Drug: Adalimumab 160/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 160/80 mg
Trial: 27175116
Drug: Adalimumab 80/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80/40 mg
Trial: 27175291
Drug: EASY model
RxNorm normalized name: Easy Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EASY model (group-based education, individualized physical activity prescription, Fitbit monitor)
Trial: 27175296
Drug: tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 5 or 10 mg twice daily
Trial: 27175296
Drug: MTX titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX titrated to 20 mg/week
Trial: 27175553
Drug: Serum 25-hydroxyvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25-hydroxyvitamin D concentration (mean total 25-OHD concentration 32.2 nmol/l, range 21.8-46.6 nmol/l)
Trial: 27175553
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity assessment using two-step euglycaemic hyperinsulinaemic clamp and HOMA2-IR
Trial: 27177028
Drug: Central augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central augmentation index (AIx_75)
Trial: 27177177
Drug: Trans sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans sodium crocetinate (TSC) with radiation therapy (RT) and temozolomide (TMZ)
Trial: 27178240
Drug: Venetoclax monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax monotherapy (20, 50, 100, 200, 400 mg ramp-up to 400 mg daily)
Trial: 27178765
Drug: Methadone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone treatment program (MTP)
Trial: 27179604
Drug: Asthma treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asthma treatment (specifics not provided)
Trial: 27180047
Drug: SMART study
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART study of antipsychotic medications
Trial: 27181924
Drug: IVF treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF treatments
Trial: 27185573
Drug: Dalotuzumab monotherapy
RxNorm normalized name: dalotuzumab
DrugBank: Dalotuzumab (DB11840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalotuzumab monotherapy at 900 mg/m2
Trial: 27185573
Drug: Dalotuzumab monotherapy
RxNorm normalized name: dalotuzumab
DrugBank: Dalotuzumab (DB11840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalotuzumab monotherapy at 1200 mg/m2
Trial: 27185573
Drug: Dalotuzumab monotherapy
RxNorm normalized name: dalotuzumab
DrugBank: Dalotuzumab (DB11840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalotuzumab monotherapy at 1500 mg/m2
Trial: 27185573
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of dalotuzumab and ridaforolimus (28 mg/m2 daily for days 1-5, repeated weekly)
Trial: 27185573
Drug: Dalotuzumab monotherapy
RxNorm normalized name: dalotuzumab
DrugBank: Dalotuzumab (DB11840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalotuzumab monotherapy
Trial: 27185799
Drug: Isavuconazole (Cresemba);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole (Cresemba); pharmacokinetic analysis based on a 2-compartment model with first-order absorption.
Trial: 27185799
Drug: Isavuconazole (Cresemba);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole (Cresemba); impact of covariates on pharmacokinetics.
Trial: 27185808
Drug: Tedizolid phosphate
RxNorm normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tedizolid phosphate (single intravenous dose)
Trial: 27188262
Drug: Conventional dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional dietary treatment (CDT)
Trial: 27188804
Drug: Miltefosine (MF)
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miltefosine (MF) for 12 weeks at an allometric dose
Trial: 27189815
Drug: NT-proBNP (≥1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP (≥1,600 pg/ml)
Trial: 27190628
Drug: Concurrent PET-CT
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent PET-CT imaging
Trial: 27190628
Drug: T-cell therapy
RxNorm normalized name: Anti-CD5 CAR T-cell therapy
DrugBank: Anti-CD5 CAR T-cell therapy (DB17279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell therapy
Trial: 27192671
Drug: Danazol 800
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 800 mg per day for 24 months
Trial: 27195129
Drug: Second-generation capsule
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation capsule colonoscopy (CC2)
Trial: 27195129
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate as a boost agent
Trial: 27196589
Drug: Split-dose uptake
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose uptake based on appointment time
Trial: 27197177
Drug: Matched therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched therapy (N = 122/188, 65%)
Trial: 27197177
Drug: Unmatched therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmatched therapy (N = 66/188, 35%)
Trial: 27198664
Drug: Ledipasvir/Sofosbuvir fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/Sofosbuvir fixed-dose combination tablet for 12 weeks
Trial: 27199429
Drug: 3BNC117 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3BNC117 infusion
Trial: 27199889
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment with five consecutive days of 2 mA cathodal tDCS over M1 for 20 min
Trial: 27199889
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment plus sham tDCS
Trial: 27206575
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg for 7 days followed by chlorthalidone 25 mg for 14 days (coadministered from day 15).
Trial: 27206575
Drug: Chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg for 13 days followed by coadministration with telmisartan 80 mg for 7 days.
Trial: 27206943
Drug: ETC-1002 120
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETC-1002 120 mg plus EZE
Trial: 27206943
Drug: ETC-1002 180
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETC-1002 180 mg plus EZE
Trial: 27207512
Drug: Type 1
RxNorm normalized name: Type 1 H substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 1 diabetes patients with PPARG G allele
Trial: 27207788
Drug: Carfilzomib 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib 70 mg/m(2) with dexamethasone (40 mg) on days 1, 8, 15, and 22; dexamethasone omitted on day 22 for cycles 9+.
Trial: 27208903
Drug: TAS-102 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-102 at 35 mg/m² b.i.d.
Trial: 27209012
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg once weekly plus methotrexate for 36 weeks
Trial: 27211104
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α)
Trial: 27211503
Drug: Magnetically Controlled
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetically Controlled Capsule Endoscopy (MCE)
Trial: 27211612
Drug: Intrathecal recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal recombinant human heparan-N-sulfatase (rhHNS) 10, 45, or 90mg via IDDD once monthly for a total of 6 doses
Trial: 27212697
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (AI) therapy after chemotherapy (CT cohort)
Trial: 27212697
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (AI) therapy as adjuvant therapy (HT cohort)
Trial: 27213629
Drug: Lipoprotein(a) apheresis
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoprotein(a) apheresis (specific immunosorbent to Lp(a)), removed weekly for 18 months.
Trial: 27215497
Drug: Daily inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily inhaled corticosteroid (≥500 μg of fluticasone propionate or equivalent) and at least 1 second controller medication
Trial: 27215497
Drug: Data collection
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data collection on medication use, asthma exacerbation data, asthma-related healthcare utilization and events raising safety concerns
Trial: 27216760
Drug: Seasonal trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal trivalent inactivated influenza vaccines (TIIVs)
Trial: 27217543
Drug: Molecularly targeted
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecularly targeted therapies (MTT)
Trial: 27222473
Drug: Ofatumumab and
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab and bendamustine combination
Trial: 27226434
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg plus low-dose dexamethasone 40 mg (20 mg for patients aged >75 years)
Trial: 27226434
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg plus low-dose dexamethasone
Trial: 27232360
Drug: Open-label ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label ketamine infusions (0.5 mg/kg over 45 minutes for the first 3 infusions; 0.75 mg/kg over 45 minutes for the last 3)
Trial: 27232579
Drug: Simtuzumab 700
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simtuzumab 700 mg intravenously every 2 weeks for 22 weeks
Trial: 27233802
Drug: Moderate CYP3A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate CYP3A inhibitors
Trial: 27233802
Drug: Strong CYP3A
RxNorm normalized name: Strongid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strong CYP3A inhibitors
Trial: 27233802
Drug: Mild and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild and moderate renal and hepatic impairment, body weight, age, race, weak CYP3A inhibitors and inducers, OATP1B1 transporter phenotype, P-gp, BCRP, and OATP1B1/OATP1B3 modulators
Trial: 27234509
Drug: (99m)Tc-PulmoBind injection
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (99m)Tc-PulmoBind injection for SPECT imaging in humans
Trial: 27234509
Drug: (99m)Tc-PulmoBind injection
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (99m)Tc-PulmoBind injection for SPECT imaging in supine dogs (n=5)
Trial: 27234642
Drug: mTOR inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mTOR inhibitor everolimus
Trial: 27236150
Drug: Telaprevir-based triple
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir-based triple therapy (telaprevir 750 mg 8-hourly, pegylated interferon 180 µg weekly, ribavirin 600 mg daily) followed by pegylated interferon and ribavirin alone for 36 weeks.
Trial: 27236390
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) monotherapy or in combination with non-biologic DMARDs, 8 mg/kg infused over 60 minutes every 4 weeks (up to 6 times)
Trial: 27237429
Drug: Sofosbuvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (400 mg, once daily) plus ribavirin (1000-1200 mg/day) for 12 weeks
Trial: 27238065
Drug: Parent training
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent training + stimulant medication + placebo (Basic)
Trial: 27238065
Drug: Parent training
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent training + stimulant + risperidone (Augmented)
Trial: 27239329
Drug: budesonide MMX
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide MMX 9 mg daily for ≤8 weeks (induction of remission)
Trial: 27239329
Drug: budesonide MMX
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide MMX added to mesalazine >2 weeks after increased/optimised mesalazine dose (late add-on)
Trial: 27239329
Drug: budesonide MMX
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide MMX as monotherapy (mono)
Trial: 27242930
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy for Insomnia (CBT-i)
Trial: 27243356
Drug: Hydrogel daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel daily disposable contact lenses (1-DAY ACUVUE MOIST)
Trial: 29098288
Drug: Hypoglossal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglossal nerve stimulator therapy
Trial: 27244882
Drug: nab-paclitaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (100 mg/m2) on day 1, 8, 22 and 29, and cisplatin (75 mg/m2) on day 1 and 22
Trial: 27245095
Drug: Panobinostat (HDAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat (HDAC inhibitor)
Trial: 27245295
Drug: Maternal Antiretroviral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal Antiretroviral Therapy (ART)
Trial: 27245312
Drug: AG-120 (mutant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-120 (mutant IDH1 inhibitor)
Trial: 27246166
Drug: Patients' self-reported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients' self-reported symptoms collected at baseline and monthly thereafter.
Trial: 27247136
Drug: Idelalisib monotherapy
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib monotherapy for 2 months followed by 6 months of combination therapy with idelalisib and ofatumumab
Trial: 27247136
Drug: Idelalisib reinitiated
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib reinitiated with steroids
Trial: 27247202
Drug: Oral tablets
RxNorm normalized name: digoxin 0.1875 MG Oral Tablets
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: 27247202
Drug: Injectable, implant,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable, implant, or vaginal ring
Trial: 27247202
Drug: Vaginal film
RxNorm normalized name: Vaginal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal film or suppository
Trial: 27252174
Drug: Toca 511
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release 5-fluorocytosine)
Trial: 27255328
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment in East Asian patients with T2D
Trial: 27255328
Drug: Noninsulin anti-hyperglycemic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninsulin anti-hyperglycemic agents usage
Trial: 27255328
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin usage
Trial: 27255678
Drug: Sunitinib 25
RxNorm normalized name: sunitinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 25 mg (dose level 1)
Trial: 27255678
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg (dose level 2)
Trial: 27256085
Drug: RSV-attributable antibiotic
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV-attributable antibiotic prescriptions